TYW1B
gene geneOn this page
Also known as RSAFD2MGC87315NCRNA00069LINC00069
Summary
TYW1B (tRNA-yW synthesizing protein 1 homolog B, HGNC:33908) is a protein-coding gene on chromosome 7q11.22-q11.23, encoding S-adenosyl-L-methionine-dependent tRNA 4-demethylwyosine synthase TYW1B (Q6NUM6). Probable component of the wybutosine biosynthesis pathway.
Wybutosine is a hypermodified guanosine found in phenylalanine tRNA. Wybutosine functions to stabilize codon-anticodon interactions during ribosome decoding and therefore supports the maintenance of the reading frame. In yeast, the homolog of this gene is essential for the synthesis of wybutosine. The human genome contains two closely related genes that putatively function in wybutosine synthesis. The open reading frame of this locus is disrupted in some individuals. Thus, this locus appears to be an evolving pseudogene, but may still be functional in some members of the population.
Source: NCBI Gene 441250 — RefSeq curated summary.
At a glance
- GWAS associations: 8
- Clinical variants (ClinVar): 85 total
- MANE Select transcript:
NM_001145440
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:33908 |
| Approved symbol | TYW1B |
| Name | tRNA-yW synthesizing protein 1 homolog B |
| Location | 7q11.22-q11.23 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | RSAFD2, MGC87315, NCRNA00069, LINC00069 |
| Ensembl gene | ENSG00000277149 |
| Ensembl biotype | protein_coding |
| Entrez | 441250 |
Gene structure
Transcript identifiers
Ensembl transcripts: 4 — 4 protein_coding
ENST00000610600, ENST00000612372, ENST00000620995, ENST00000902318
RefSeq mRNA: 3 — MANE Select: NM_001145440
NM_001145440, NM_001412179, NM_001412180
CCDS: CCDS69309
Canonical transcript exons
ENST00000620995 — 14 exons
| Exon | Start | End |
|---|---|---|
| ENSE00003717112 | 72807066 | 72807356 |
| ENSE00003723148 | 72694687 | 72694822 |
| ENSE00003724262 | 72826855 | 72826985 |
| ENSE00003726063 | 72713621 | 72713798 |
| ENSE00003728695 | 72828072 | 72828200 |
| ENSE00003729832 | 72777416 | 72777533 |
| ENSE00003735223 | 72802400 | 72802522 |
| ENSE00003735267 | 72574513 | 72575719 |
| ENSE00003739660 | 72616672 | 72616839 |
| ENSE00003742589 | 72728822 | 72728931 |
| ENSE00003744820 | 72628887 | 72628997 |
| ENSE00003747077 | 72815380 | 72815481 |
| ENSE00003753156 | 72744484 | 72744601 |
| ENSE00003753188 | 72810471 | 72810665 |
Expression profiles
Bgee: expression breadth ubiquitous, 134 present calls, max score 92.09.
FANTOM5 (CAGE): breadth ubiquitous, TPM avg 6.4695 / max 110.6306, expressed in 1486 samples.
FANTOM5 promoters (2 alternative TSS)
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 84280 | 5.7925 | 1452 |
| 84279 | 0.6770 | 341 |
Top tissues by expression
134 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| sural nerve | UBERON:0015488 | 92.09 | gold quality |
| male germ line stem cell (sensu Vertebrata) in testis | CL:0000089 ∩ UBERON:0000473 | 83.95 | gold quality |
| primordial germ cell in gonad | CL:0000670 ∩ UBERON:0000991 | 83.56 | gold quality |
| calcaneal tendon | UBERON:0003701 | 76.72 | gold quality |
| bone marrow cell | CL:0002092 | 74.86 | gold quality |
| tonsil | UBERON:0002372 | 74.36 | gold quality |
| granulocyte | CL:0000094 | 73.54 | gold quality |
| skeletal muscle tissue | UBERON:0001134 | 73.31 | gold quality |
| gastrocnemius | UBERON:0001388 | 72.72 | gold quality |
| ventricular zone | UBERON:0003053 | 72.58 | gold quality |
| bone marrow | UBERON:0002371 | 72.50 | gold quality |
| muscle of leg | UBERON:0001383 | 71.79 | gold quality |
| corpus callosum | UBERON:0002336 | 71.61 | gold quality |
| muscle tissue | UBERON:0002385 | 71.24 | gold quality |
| endocervix | UBERON:0000458 | 71.22 | gold quality |
| uterine cervix | UBERON:0000002 | 71.16 | gold quality |
| ectocervix | UBERON:0012249 | 70.63 | gold quality |
| urinary bladder | UBERON:0001255 | 70.23 | gold quality |
| adrenal tissue | UBERON:0018303 | 70.21 | gold quality |
| right ovary | UBERON:0002118 | 70.17 | gold quality |
| ovary | UBERON:0000992 | 69.52 | gold quality |
| liver | UBERON:0002107 | 68.92 | gold quality |
| left ovary | UBERON:0002119 | 68.78 | gold quality |
| leukocyte | CL:0000738 | 68.54 | gold quality |
| placenta | UBERON:0001987 | 68.37 | gold quality |
| mucosa of transverse colon | UBERON:0004991 | 68.29 | gold quality |
| lower esophagus mucosa | UBERON:0035834 | 68.20 | gold quality |
| popliteal artery | UBERON:0002250 | 68.00 | gold quality |
| tibial artery | UBERON:0007610 | 67.99 | gold quality |
| vagina | UBERON:0000996 | 67.97 | gold quality |
Single-cell (SCXA)
Detected in 2 experiment(s), a significant marker in 1.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-ANND-3 | yes | 4.09 |
| E-MTAB-4850 | no | 6.82 |
Regulation
Is transcription factor: no
miRNA regulators (miRDB)
39 targeting TYW1B, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-4747-5P | 100.00 | 67.90 | 2681 |
| HSA-MIR-5196-5P | 100.00 | 67.98 | 2761 |
| HSA-MIR-4795-3P | 100.00 | 74.62 | 4024 |
| HSA-MIR-4531 | 99.99 | 69.70 | 3181 |
| HSA-MIR-186-5P | 99.99 | 70.83 | 3707 |
| HSA-MIR-570-3P | 99.96 | 72.41 | 4910 |
| HSA-MIR-9983-3P | 99.94 | 71.48 | 3631 |
| HSA-MIR-454-3P | 99.91 | 74.01 | 1925 |
| HSA-MIR-130A-3P | 99.90 | 73.31 | 1861 |
| HSA-MIR-130B-3P | 99.90 | 73.27 | 1850 |
| HSA-MIR-301A-3P | 99.90 | 73.15 | 1839 |
| HSA-MIR-301B-3P | 99.90 | 73.19 | 1836 |
| HSA-MIR-3666 | 99.90 | 73.24 | 1833 |
| HSA-MIR-4295 | 99.90 | 73.11 | 1838 |
| HSA-MIR-129-5P | 99.88 | 70.26 | 3273 |
| HSA-MIR-369-3P | 99.85 | 70.52 | 2264 |
| HSA-MIR-3680-3P | 99.75 | 72.51 | 3095 |
| HSA-MIR-3059-5P | 99.70 | 69.93 | 2491 |
| HSA-MIR-3202 | 99.66 | 67.70 | 2737 |
| HSA-MIR-325 | 99.58 | 66.55 | 358 |
| HSA-MIR-6716-5P | 99.56 | 68.62 | 1244 |
| HSA-MIR-297 | 99.40 | 69.58 | 1418 |
| HSA-MIR-1244 | 99.33 | 68.38 | 832 |
| HSA-MIR-877-3P | 99.09 | 68.10 | 1637 |
| HSA-MIR-6749-3P | 99.00 | 65.73 | 1443 |
| HSA-MIR-6876-3P | 98.97 | 65.69 | 765 |
| HSA-MIR-455-3P | 98.94 | 67.68 | 878 |
| HSA-MIR-626 | 98.89 | 66.21 | 762 |
| HSA-MIR-3149 | 98.77 | 67.13 | 1639 |
| HSA-MIR-496 | 98.66 | 69.80 | 931 |
Cross-species orthologs
3 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| danio_rerio | tyw1 | ENSDARG00000062987 |
| mus_musculus | Tyw1 | ENSMUSG00000056310 |
| rattus_norvegicus | Tyw1 | ENSRNOG00000024352 |
Paralogs (1): TYW1 (ENSG00000198874)
Protein
Protein identifiers
S-adenosyl-L-methionine-dependent tRNA 4-demethylwyosine synthase TYW1B — Q6NUM6 (reviewed: Q6NUM6)
Alternative names: Radical S-adenosyl methionine and flavodoxin domain-containing protein 2, tRNA wybutosine-synthesizing protein 1 homolog B
All UniProt accessions (3): Q6NUM6, A0A087WWV6, A0A087X1V1
UniProt curated annotations — full annotation on UniProt →
Function. Probable component of the wybutosine biosynthesis pathway. Wybutosine is a hyper modified guanosine with a tricyclic base found at the 3’-position adjacent to the anticodon of eukaryotic phenylalanine tRNA. Catalyzes the condensation of N-methylguanine with 2 carbon atoms from pyruvate to form the tricyclic 4-demethylwyosine, an intermediate in wybutosine biosynthesis.
Cofactor. Binds 1 [4Fe-4S] cluster. The cluster is coordinated with 3 cysteines and an exchangeable S-adenosyl-L-methionine.
Pathway. tRNA modification; wybutosine-tRNA(Phe) biosynthesis.
Similarity. Belongs to the TYW1 family.
Isoforms (2)
| UniProt ID | Names | Canonical? |
|---|---|---|
| Q6NUM6-1 | 1 | yes |
| Q6NUM6-2 | 2 |
RefSeq proteins (3): NP_001138912, NP_001399108, NP_001399109 (=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR001094 | Flavdoxin-like | Domain |
| IPR007197 | rSAM | Domain |
| IPR008254 | Flavodoxin/NO_synth | Domain |
| IPR013785 | Aldolase_TIM | Homologous_superfamily |
| IPR013917 | tRNA_wybutosine-synth | Domain |
| IPR029039 | Flavoprotein-like_sf | Homologous_superfamily |
| IPR034556 | tRNA_wybutosine-synthase | Family |
| IPR058240 | rSAM_sf | Homologous_superfamily |
Pfam: PF00258, PF04055, PF08608
Catalyzed reactions (Rhea), 1 shown:
- N(1)-methylguanosine(37) in tRNA(Phe) + pyruvate + S-adenosyl-L-methionine = 4-demethylwyosine(37) in tRNA(Phe) + 5’-deoxyadenosine + L-methionine + CO2 + H2O (RHEA:36347)
UniProt features (14 total): binding site 5, compositionally biased region 3, domain 2, chain 1, splice variant 1, sequence conflict 1, region of interest 1
Structure
Experimental structures (PDB)
0 structures.
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-Q6NUM6-F1 | 76.40 | 0.44 |
Functional residue map
Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.
Ligand- & substrate-binding residues (5): 356; 359; 43–47; 130–162; 352
Function
Pathways and Gene Ontology
Reactome pathways
0 pathways
MSigDB gene sets: 47 (showing top):
GOBP_TRNA_METABOLIC_PROCESS, GOBP_CARBOHYDRATE_DERIVATIVE_METABOLIC_PROCESS, GOBP_RNA_MODIFICATION, GOBP_CARBOHYDRATE_DERIVATIVE_BIOSYNTHETIC_PROCESS, chr7q11, GOBP_GLYCOSYL_COMPOUND_BIOSYNTHETIC_PROCESS, GOBP_TRNA_PROCESSING, GOBP_TRNA_MODIFICATION, GOMF_FMN_BINDING, GOMF_CARBON_CARBON_LYASE_ACTIVITY, GOMF_METAL_CLUSTER_BINDING, GOMF_4_IRON_4_SULFUR_CLUSTER_BINDING, GOMF_OXO_ACID_LYASE_ACTIVITY, GOMF_CATALYTIC_ACTIVITY_ACTING_ON_RNA, GOMF_CATALYTIC_ACTIVITY_ACTING_ON_A_TRNA
GO Biological Process (2): wybutosine biosynthetic process (GO:0031591), tRNA processing (GO:0008033)
GO Molecular Function (9): FMN binding (GO:0010181), metal ion binding (GO:0046872), 4 iron, 4 sulfur cluster binding (GO:0051539), tRNA-4-demethylwyosine synthase activity (GO:0102521), nucleotide binding (GO:0000166), catalytic activity (GO:0003824), protein binding (GO:0005515), lyase activity (GO:0016829), iron-sulfur cluster binding (GO:0051536)
GO Cellular Component (1): membrane (GO:0016020)
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| tRNA modification | 1 |
| glycosyl compound biosynthetic process | 1 |
| RNA processing | 1 |
| tRNA metabolic process | 1 |
| ribonucleotide binding | 1 |
| anion binding | 1 |
| cation binding | 1 |
| iron-sulfur cluster binding | 1 |
| oxo-acid-lyase activity | 1 |
| catalytic activity, acting on a tRNA | 1 |
| nucleoside phosphate binding | 1 |
| heterocyclic compound binding | 1 |
| molecular_function | 1 |
| binding | 1 |
| catalytic activity | 1 |
| metal cluster binding | 1 |
| cellular anatomical structure | 1 |
Protein interactions and networks
STRING
538 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| TYW1B | OSBPL7 | Q9BZF2 | 571 |
| TYW1B | MTARC1 | Q5VT66 | 519 |
| TYW1B | COBLL1 | Q53SF7 | 447 |
| TYW1B | NBPF9 | P0DPF3 | 431 |
| TYW1B | ABCA8 | O94911 | 419 |
| TYW1B | DEFB132 | Q7Z7B7 | 402 |
| TYW1B | DPY19L3 | Q6ZPD9 | 399 |
| TYW1B | FAM110A | Q9BQ89 | 395 |
| TYW1B | KLF14 | Q8TD94 | 380 |
| TYW1B | DIPK1A | Q5T7M9 | 371 |
| TYW1B | ANGPTL3 | Q9Y5C1 | 370 |
| TYW1B | IQCE | Q6IPM2 | 366 |
| TYW1B | IL6R | P08887 | 365 |
| TYW1B | SP6 | Q3SY56 | 352 |
| TYW1B | JMJD1C | Q15652 | 350 |
| TYW1B | EML5 | Q05BV3 | 350 |
IntAct
26 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| RANBP6 | SLC27A2 | psi-mi:“MI:0914”(association) | 0.640 |
| TAS2R19 | TYW1B | psi-mi:“MI:0915”(physical association) | 0.560 |
| POMK | TMEM120B | psi-mi:“MI:0914”(association) | 0.530 |
| PTGER3 | PIK3R2 | psi-mi:“MI:0914”(association) | 0.530 |
| SPACA1 | GOLIM4 | psi-mi:“MI:0914”(association) | 0.530 |
| TEX264 | PER1 | psi-mi:“MI:0914”(association) | 0.530 |
| ARL15 | SLC25A20 | psi-mi:“MI:0914”(association) | 0.530 |
| TCIRG1 | AP3D1 | psi-mi:“MI:0914”(association) | 0.530 |
| HEATR3 | SLC27A2 | psi-mi:“MI:0914”(association) | 0.530 |
| HTATSF1 | psi-mi:“MI:0915”(physical association) | 0.400 | |
| SLC18A1 | LIMK2 | psi-mi:“MI:0914”(association) | 0.350 |
| EDNRB | EXOC5 | psi-mi:“MI:0914”(association) | 0.350 |
| CDKAL1 | CIAO1 | psi-mi:“MI:0914”(association) | 0.350 |
| ENTPD4 | TYW1B | psi-mi:“MI:0914”(association) | 0.350 |
| SPACA1 | ESYT2 | psi-mi:“MI:0914”(association) | 0.350 |
| KLRC4 | RAP1BL | psi-mi:“MI:0914”(association) | 0.350 |
| HFE | PODXL | psi-mi:“MI:0914”(association) | 0.350 |
| CD3D | CLGN | psi-mi:“MI:0914”(association) | 0.350 |
| KCNE3 | TMEM131L | psi-mi:“MI:0914”(association) | 0.350 |
| TAS2R19 | TYW1B | psi-mi:“MI:0915”(physical association) | 0.000 |
BioGRID (34): TYW1B (Affinity Capture-MS), TYW1B (Affinity Capture-MS), TYW1B (Affinity Capture-MS), TYW1B (Affinity Capture-MS), TYW1B (Affinity Capture-MS), TYW1B (Affinity Capture-MS), TYW1B (Affinity Capture-MS), TYW1B (Affinity Capture-MS), TYW1B (Affinity Capture-MS), TYW1B (Affinity Capture-MS), TYW1B (Affinity Capture-MS), TYW1B (Affinity Capture-MS), TYW1B (Affinity Capture-MS), TYW1B (Affinity Capture-MS), TYW1B (Affinity Capture-MS)
ESM2 similar proteins: A0A0K3AXH1, A0A125YYR0, A0A7J6K9S4, B5SNZ6, B8PYG1, B9EHT4, C5E2E7, D0Z5N4, F1RD40, F4I2J8, F4IIZ9, F4J6F6, F4KFS5, F5HB62, G5EG86, O04064, O19132, O48767, O48791, O64953, P23915, P26358, P32351, P34335, P49584, Q0WUY1, Q2PAY3, Q5R4R7, Q60JJ0, Q66654, Q6NUM6, Q6X4W1, Q6XL73, Q755A9, Q75QN6, Q80TL4, Q86ME2, Q8BFX3, Q8GX05, Q8SVC0
Diamond homologs: A0A2U1KZS6, A0A2U1LIM9, A0A7T9QPQ1, A2QS05, A2WZT1, A2Y8E0, A5F3I4, C5YJG8, O04397, O04977, O08336, O08394, O19114, O32214, O54705, O62699, P00388, P00389, P00454, P00455, P04175, P10933, P16435, P16603, P19618, P21890, P29477, P35228, P36587, P37039, P37040, P37116, P37201, P41343, P41344, P41346, P47169, P50126, P79290, Q00141
SIGNOR signaling
0 interactions.
Disease & clinical
Clinical variants and AI predictions
ClinVar
85 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 66 |
| Likely benign | 4 |
| Benign | 1 |
Top pathogenic / likely-pathogenic (0)
SpliceAI
3647 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 7:72575715:TTAAA:T | acceptor_gain | 1.0000 |
| 7:72575716:TAAA:T | acceptor_gain | 1.0000 |
| 7:72575717:AAACT:A | acceptor_loss | 1.0000 |
| 7:72575718:AACTG:A | acceptor_loss | 1.0000 |
| 7:72575719:ACTG:A | acceptor_loss | 1.0000 |
| 7:72575720:C:CC | acceptor_gain | 1.0000 |
| 7:72575720:C:CG | acceptor_loss | 1.0000 |
| 7:72575721:T:G | acceptor_loss | 1.0000 |
| 7:72616666:TCTTA:T | donor_loss | 1.0000 |
| 7:72616667:CTTA:C | donor_loss | 1.0000 |
| 7:72616668:TTACC:T | donor_loss | 1.0000 |
| 7:72616669:TAC:T | donor_loss | 1.0000 |
| 7:72616670:ACCT:A | donor_loss | 1.0000 |
| 7:72616671:C:G | donor_loss | 1.0000 |
| 7:72616671:CCTTT:C | donor_gain | 1.0000 |
| 7:72628881:GCTTA:G | donor_loss | 1.0000 |
| 7:72628882:CTTA:C | donor_loss | 1.0000 |
| 7:72628883:TTAC:T | donor_loss | 1.0000 |
| 7:72628884:TACCT:T | donor_loss | 1.0000 |
| 7:72628885:A:AC | donor_gain | 1.0000 |
| 7:72628885:A:C | donor_loss | 1.0000 |
| 7:72628886:C:CC | donor_gain | 1.0000 |
| 7:72628886:CCTT:C | donor_gain | 1.0000 |
| 7:72628993:TGTTG:T | acceptor_gain | 1.0000 |
| 7:72628994:GTTG:G | acceptor_gain | 1.0000 |
| 7:72628995:TTG:T | acceptor_gain | 1.0000 |
| 7:72628995:TTGCT:T | acceptor_loss | 1.0000 |
| 7:72628996:TG:T | acceptor_gain | 1.0000 |
| 7:72628997:GC:G | acceptor_loss | 1.0000 |
| 7:72628998:C:A | acceptor_loss | 1.0000 |
AlphaMissense
4498 scored. Top likely-pathogenic:
| Variant | Protein change | am_pathogenicity |
|---|---|---|
| 7:72575672:G:C | F611L | 0.881 |
| 7:72575672:G:T | F611L | 0.881 |
| 7:72575674:A:G | F611L | 0.881 |
| 7:72575717:A:C | F596L | 0.874 |
| 7:72575717:A:T | F596L | 0.874 |
| 7:72575719:A:G | F596L | 0.874 |
| 7:72713656:G:C | F445L | 0.874 |
| 7:72713656:G:T | F445L | 0.874 |
| 7:72713658:A:G | F445L | 0.874 |
| 7:72575624:G:C | F627L | 0.873 |
| 7:72575624:G:T | F627L | 0.873 |
| 7:72575626:A:G | F627L | 0.873 |
| 7:72713659:G:C | S444R | 0.872 |
| 7:72713659:G:T | S444R | 0.872 |
| 7:72713661:T:G | S444R | 0.872 |
| 7:72713635:A:C | F452L | 0.861 |
| 7:72713635:A:T | F452L | 0.861 |
| 7:72713637:A:G | F452L | 0.861 |
| 7:72575701:A:G | W602R | 0.854 |
| 7:72575701:A:T | W602R | 0.854 |
| 7:72810510:A:C | F131L | 0.853 |
| 7:72810510:A:T | F131L | 0.853 |
| 7:72810512:A:G | F131L | 0.853 |
| 7:72616759:A:C | F566L | 0.843 |
| 7:72616759:A:T | F566L | 0.843 |
| 7:72616761:A:G | F566L | 0.843 |
| 7:72810477:G:C | F142L | 0.811 |
| 7:72810477:G:T | F142L | 0.811 |
| 7:72810479:A:G | F142L | 0.811 |
| 7:72744492:G:C | F358L | 0.805 |
dbSNP variants (sampled 300 via entrez): RS1000025959 (7:72753047 C>T), RS1000305732 (7:72754704 C>T), RS1001067332 (7:72759678 T>A), RS1001346729 (7:72761361 T>C,G), RS1001579949 (7:72756093 A>T), RS1003070739 (7:72762672 T>C), RS1003356005 (7:72805709 G>C), RS1003408486 (7:72805317 A>G), RS1003525608 (7:72752383 T>C), RS1003808607 (7:72752676 A>G), RS1003857949 (7:72756965 C>A,G), RS1004442123 (7:72751200 G>A), RS1005401654 (7:72763993 A>T), RS1005586305 (7:72757906 C>T), RS1005761993 (7:72805267 C>A)
Disease associations
OMIM: gene `` | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
8 associations (top):
| Study | Trait | p-value |
|---|---|---|
| GCST000758_32 | Triglycerides | 1.000000e-09 |
| GCST002216_8 | Triglycerides | 3.000000e-06 |
| GCST004237_20 | Triglyceride levels | 2.000000e-08 |
| GCST008151_111 | Waist circumference | 3.000000e-06 |
| GCST008160_63 | Waist circumference | 3.000000e-06 |
| GCST009363_14 | Triglyceride levels x short total sleep time interaction (2df test) | 1.000000e-56 |
| GCST009364_13 | Triglyceride levels x long total sleep time interaction (2df test) | 2.000000e-57 |
| GCST009364_14 | Triglyceride levels x long total sleep time interaction (2df test) | 8.000000e-11 |
EFO canonical traits (1, from GWAS)
| EFO ID | Trait name |
|---|---|
| EFO:0004530 | triglyceride measurement |
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
CTD chemical–gene interactions
9 total (human), top 9 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| sodium arsenite | increases expression | 1 |
| abrine | increases expression | 1 |
| licochalcone B | increases expression | 1 |
| Sunitinib | decreases expression | 1 |
| Benzo(a)pyrene | increases methylation | 1 |
| Urethane | increases expression | 1 |
| Aflatoxin B1 | increases methylation | 1 |
| Okadaic Acid | increases expression | 1 |
| Acrylamide | increases expression | 1 |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.